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ST-Segment Elevation Myocardial Infarction Undergoing
Primary Percutaneous Coronary Intervention
The LIPSIA-N-ACC (Prospective, Single-Blind,
Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS
Coronary Intervention Acute Myocardial Infarction N-ACC) Trial
Holger Thiele, MD,* Lysann Hildebrand, BSC,* Carmen Schirdewahn, BSC,* Ingo Eitel, MD,*
Volker Adams, PHD,* Georg Fuernau, MD,* Sandra Erbs, MD,* Axel Linke, MD,*
Klaus-Werner Diederich, MD,* Marek Nowak, MD,* Steffen Desch, MD,* Matthias Gutberlet, MD,†
Gerhard Schuler, MD*
Leipzig, Germany
Objectives The aim of this randomized, single-blind, controlled trial was to assess N-acetylcysteine effects on contrast-
induced nephropathy and reperfusion injury in ST-segment elevation myocardial infarction patients undergoing
primary angioplasty with moderate contrast volumes.
Background High-dose N-acetylcysteine reduced the incidence of contrast-induced nephropathy in patients with high contrast
volumes and reduced reperfusion injury in animal trials.
Methods Patients undergoing primary angioplasty were randomized to either high-dose N-acetylcysteine (2  1,200 mg/day
for 48 h; n  126) or placebo plus optimal hydration (n  125). The 2 primary end points were: 1) the occurrence of
25% increase in serum creatinine level 72 h after randomization; and 2) a reduction in reperfusion injury mea-
sured as myocardial salvage index by magnetic resonance imaging.
Results The median volume of an iso-osmolar contrast agent during angiography was 180 ml (interquartile range [IQR]
140 to 230 ml) in the N-acetylcysteine and 160 ml (IQR 120 to 220 ml) in the placebo group (p  0.20). The
primary end point contrast-induced nephropathy occurred in 14% of the N-acetylcysteine group and in 20% of
the placebo group (p  0.28). The myocardial salvage index was also not different between both treatment
groups (43.5; IQR 25.4 to 71.9 vs. 51.5; IQR 29.5 to 75.3; p  0.36). Activated oxygen protein products and oxi-
dized low-density lipoprotein as markers for oxidative stress were reduced by as much as 20% in the
N-acetylcysteine group (p  0.05), whereas no change was evident in the placebo group.
Conclusions High-dose intravenous N-acetylcysteine reduces oxidative stress. However, it does not provide an additional clini-
cal benefit to placebo with respect to CIN and myocardial reperfusion injury in nonselected patients undergoing
angioplasty with moderate doses of contrast medium and optimal hydration. (Myocardial Salvage and Contrast
Dye Induced Nephropathy Reduction by N-Acetylcysteine [LIPSIA-N-ACC]; NCT00463749) (J Am Coll Cardiol
2010;55:2201–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.091s
t
finfarct size is a major determinant of mortality in acute
yocardial infarction (AMI). Currently, the most effective way
o limit infarct size is to reperfuse the infarct-related artery as
rom the Departments of *Internal Medicine–Cardiology and †Radiology, Univer-
ity of Leipzig Heart Center, Leipzig, Germany.r
Manuscript received June 17, 2009; revised manuscript received August 26, 2009,
ccepted August 31, 2009.oon as possible, preferably by percutaneous coronary interven-
ion (PCI) (1–3). Although reperfusion is undoubtedly bene-
See page 2210
cial, reperfusion itself can induce processes of myocardial
eperfusion injury resulting in additional death of cardiomyo-
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N-Acetylcysteine in Infarction May 18, 2010:2201–9cytes that were viable at the time of
reperfusion (4). Oxidative stress is
one of the major factors contribut-
ing to reperfusion injury (4,5).
N-acetylcysteine might reduce the
infarct size by its antioxidant prop-
erties (6,7).
In addition, patients with AMI
treated by PCI are at increased risk
of contrast-induced nephropathy
(CIN), which is associated with
prolonged hospitalization and
adverse clinical outcome (8–10).
Major factors associated with an
increased CIN risk are impaired
systemic perfusion, large contrast
volume, and the inability to per-
form adequate prophylaxis. In a
recent trial, optimal hydration in
ombination with high-dose N-acetylcysteine prevented
IN in patients with relatively high contrast doses (8).
The low cost of N-acetylcysteine, its ease of administration,
nd its limited adverse effects are compelling reasons to
urther investigate its role in patients with AMI. This
andomized, single-blind, placebo-controlled trial was
herefore conducted to assess the effects of high-dose
-acetylcysteine on reperfusion injury and CIN prevention
fter moderate contrast doses.
ethods
tudy population. This trial was conducted at the Uni-
ersity of Leipzig–Heart Center between November 2006
nd February 2008 in accordance with the principles of
ood clinical practice and the Declaration of Helsinki.
he study protocol was approved by the local ethics
ommittee and the Bundesinstitut für Arzneimittel und
edizinprodukte, Germany. All patients gave written
nformed consent.
Patients with AMI undergoing primary PCI were eligible
f their symptoms lasted 12 h and if they had ST-segment
levation of 0.1 mV in 2 extremity leads or 0.2 mV in
2 pre-cordial leads. Exclusion criteria were previous fibri-
olysis 12 h, known N-acetylcysteine allergy, chronic
ialysis, and pregnancy. Furthermore, patients with contra-
ndications to magnetic resonance imaging (MRI) at study
ntry were excluded.
tudy protocol. Eligible patients were randomly as-
igned in a 1:1 ratio to receive high-dose N-acetylcysteine
r matching placebo using computer-generated random
umbers. N-acetylcysteine (ACC inject; Hexal AG, Hol-
kirchen, Germany) patients received an intravenous
olus of 1,200 mg before angioplasty and 1,200 mg
ntravenously twice daily for the 48 h after PCI (total
ose 6,000 mg), whereas control patients received match-
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
AOPP  advanced
oxidation protein products
CIN  contrast-induced
nephropathy
IQR  interquartile range
MRI  magnetic resonance
imaging
MSI  myocardial salvage
index
PCI  percutaneous
coronary intervention
TIMI  Thrombolysis In
Myocardial Infarctionng placebo (10 ml of NaCl 0.9% at each injection). After TCI, all treated and control patients underwent hydration
ith intravenous NaCl (0.9%) infusion at a rate of 1
l/kg of body weight per h for 12 h (or 0.5 ml/kg/h in
vert heart failure). Patients and investigators assessing
he outcomes were unaware of the group assignment.
rimary angioplasty and subsequent treatment. PCI was
erformed according to standard clinical practice using a
onionic, low-osmolality contrast agent, iopromide (Ultra-
ist 370, Schering, Berlin, Germany). The use of bare metal
r drug-eluting stents was left to the interventionalist’s
iscretion. Additional use of thrombectomy was recom-
ended depending on thrombus in the infarct-related
rtery. All patients received 500 mg of aspirin and heparin
60 U/kg of body weight) intravenously before PCI. Clo-
idogrel (600 mg orally during PCI, followed by 75 mg/day
or at least 12 months) was mandatory. Aspirin was given
ndefinitely at a dose of 100 mg/day (1).
utcomes. The 2 primary outcomes were: 1) the occur-
ence of CIN within 72 h after PCI; and 2) reperfusion
njury measured as the myocardial salvage index (MSI) by
RI. The secondary outcome measure for CIN was the
eed for temporal renal replacement therapy. For reperfu-
ion injury, the secondary outcome parameters were infarct
ize and microvascular obstruction measured by MRI (11),
arly ST-segment resolution (11), and infarct size measured
s the area under the curve of creatine kinase-MB release
erived from measurements every 6 h over 2 days. Oxidative
tress occurring before, immediately after, and within 72 h
fter PCI was measured for further causal explanations; in
ddition, a clinical composite of major adverse cardiovascu-
ar events within 6 months after randomization was
ssessed.
efinition of nephropathy. CIN was defined as an
ncrease in serum creatinine concentration of 25% from
aseline within 72 h after PCI. Creatinine concentration
as measured at admission and every day in the morning
or the next 3 days. Creatinine clearance was estimated
sing the Modification of Diet in Renal Disease study
quation (12).
efinitions of reperfusion injury. Reperfusion injury
as determined as MSI derived from MRI at days 2 to 4
fter the index event. The area at risk, infarct size, and
icrovascular obstruction were acquired on a 1.5-T
canner (Philips Intera CV, Best, the Netherlands). Left
entricular function was assessed by a steady-state free
recession technique. For area at risk determination,
hort-axis slices covering the whole ventricle using a
2-weighted turbo spin echo sequence were obtained
13,14). Early and delayed enhancement images covering
he whole ventricle were acquired approximately 1 and 15
in after intravenous administration of 0.2 mmol/kg of
ody weight of gadobutrol (Gadovist, Schering) (11).
otal left ventricular myocardial mass, early and late
icrovascular obstruction, area at risk, and infarct size
ere assessed manually by fully blinded operators (11,15).
he following parameters were calculated as described
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May 18, 2010:2201–9 N-Acetylcysteine in Infarctionreviously (11,16): 1) area at risk  volume edema/
olume left ventricular mass; 2) % infarct size  volume
nfarct/volume left ventricular mass; % microvascular
bstruction  volume microvascular obstruction/volume
eft ventricular mass; and 3) myocardial salvage area at risk
infarct size; 4) MSI area at risk infarct size/area at risk.
he core laboratory has excellent reproducibility for infarct size
easurement, and the bias and limits of agreement for MSI
ssessment are 0.3  5.0 (15).
T-segment resolution. The percentage of ST-segment
esolution (approximately 90 min after PCI) was calculated
s described previously (16).
nfarct size measured by enzyme release. Infarct size was
ndirectly measured by the area under the curve of creatine
inase-MB release derived from measurements every 6 h
ver 2 days.
xidative stress. For oxidative stress measurements be-
ore, directly after PCI, and subsequently for up to 3 days,
enous blood samples were collected and plasma was stored
t 80°C until used for measurements. Parameters mea-
ured by enzyme-linked immunosorbent assay (Immundi-
gnostik, Bensheim, Germany) as indirect markers for
xidative stress included advanced oxidation protein prod-
cts (AOPPs) and oxidized low-density lipoprotein.
linical end points. Clinical end points were a composite
f death, reinfarction, and the occurrence of new congestive
eart failure 6 months after randomization. Post-hospital
Figure 1 Study Flow and Distribution of Procedures
Study flow, excluded patients, and number of patients for end point analysis in ea
CIN  contrast-induced nephropathy; MRI  magnetic resonance imaging; STEMIollow-up included one 6-month outpatient visit. The
iagnosis of reinfarction was based on previous definitions
11). New heart failure was defined as any congestive heart
ailure (rales, dyspnea, New York Heart Association func-
ional class III/IV) occurring 24 h after the index event.
utcomes were adjudicated by a clinical events committee
naware of the patient’s assigned treatment.
tatistical analysis. The number of patients included in
his study was based on a previous trial of N-acetylcysteine
or CIN prevention (8). Assuming a slightly lower inci-
ence, because of lower contrast volumes, we assumed a
eduction in the average nephropathy rate from 25% to 10%
n N-acetylcysteine–treated patients. The inclusion of 113
atients in each group allowed for a statistical power of 80%
ith a type I error of 0.05.
For reperfusion injury, we assumed an MSI of 50  15%
17). With a power of 80% and a 2-sided  value of 0.05, we
stimated that 100 patients would be required in each group
o detect an absolute difference of 6% in MSI. A total of 251
atients were included to allow for the possibility of missing
RI studies and missing creatinine values.
Continuous data are reported as medians and interquartile
anges (IQRs), if not otherwise stated. Categorical data are
resented as absolute values and percentages. Differences be-
ween treatment groups were assessed by the Fisher exact or
he chi-square test for categorical variables and by the Student
tment group.
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N-Acetylcysteine in Infarction May 18, 2010:2201–9test for continuous data with normal distribution. Otherwise
he nonparametric Mann-Whitney test was used.
Serial creatinine concentrations, creatinine clearance, and
xidative stress parameters were compared within and between
roups using repeated-measures analysis of variance. A multi-
ariable logistic regression model including age, sex, diabetes,
ypertension, baseline serum creatinine concentration, creati-
ine clearance, contrast volume, and left ventricular ejection
raction was applied to assess confounders for nephropathy.
or reperfusion injury, symptom duration, infarct location, and
re- and post-interventional Thrombolysis In Myocardial In-
arction (TIMI) flow were added to a linear multivariable
odel. All statistical tests were performed with SPSS software,
ersion 15.0 (SPSS, Inc., Chicago, Illinois). A 2-tailed p value
0.05 was considered statistically significant.
esults
f the 251 patients enrolled, 126 were randomly assigned to
-acetylcysteine and 125 to placebo (Fig. 1). Only 7 eligible
Main Patient CharacteristicsTable 1 Main Patient Characteristics
Variable
N-Ac
(
Age, yrs 68
Male sex 89
Cardiovascular risk factors
Current smoking 40
Hypertension 89
Hypercholesterolemia 40
Diabetes mellitus 32
Previous myocardial infarction 13
Previous coronary artery bypass grafting 1
Anterior myocardial infarction 57
Number of diseased vessels
0 2
1 62
2 32
3 30
Killip class on admission
1 87
2 32
3 4
4 3
Intra-aortic balloon pump 7
Concomitant medications
Beta-blockers 124
ACE-inhibitors/AT-1-antagonist 124
Aspirin 125
Clopidogrel 124
Statins 125
Aldosterone antagonist 5
Glycoprotein IIb/IIIa inhibitor 117
Serum creatinine, mol/l 81
Creatinine clearance, ml/min 85
Volume of contrast agent, ml 180
Volume of contrast agent 300 ml 19Values are median (interquartile range) or n (%).
ACE  angiotensin-converting enzyme; AT-1  angiotensin 1.atients were not included during the study period. All
atients received the assigned treatment. The baseline
haracteristics and medication were similar between groups
Table 1). There were no adverse events during
-acetylcysteine administration. Reperfusion times were
imilar with a median time from symptom onset to PCI of
30 min (IQR 147 to 375 min) and 263 min (IQR 160 to
22 min; p  0.28), respectively. The door to balloon time
as 27 min (IQR 20 to 35 min) versus 26 min (IQR 22 to
5 min; p  0.66).
In the N-acetylcysteine group, 2 patients had apical
allooning syndrome and in the placebo group, 1 had
yocarditis; thus, these patients had normal coronary arter-
es. In all other patients, PCI was performed. In 17% versus
2%, drug-eluting stents were used (p  0.34). Post-PCI
IMI flow grade 3 was achieved in 91% versus 92% (p 
.89). In the placebo group, 2 patients died during cathe-
erization with the consequence of no further assessment of
reatinine and oxidative stress parameters (Fig. 1).
steine
6)
Placebo
(n  125) p Value
5) 68 (56–76) 0.33
82 (66) 0.47
54 (43) 0.08
92 (74) 0.70
46 (37) 0.48
41 (33) 0.25
16 (13) 0.68
4 (3) 0.36
64 (51) 0.41
0.95
1 (1)
62 (50)
33 (26)
29 (23)
0.78
84 (67)
30 (24)
7 (6)
4 (3)
7 (6) 0.80
122 (98) 0.99
122 (98) 0.99
124 (99) 0.62
123 (98) 0.00
123 (98) 0.99
5 (4) 0.76
118 (94) 0.81
7) 78 (67–90) 0.32
7) 86 (69–99) 0.59
230) 160 (120–220) 0.20
17 (14) 0.88etylcy
n  12
(57–7
(71)
(32)
(71)
(32)
(25)
(10)
(1)
(45)
(2)
(49)
(25)
(24)
(69)
(26)
(3)
(2)
(6)
(98)
(98)
(99)
(98)
(99)
(4)
(93)
(69–9
(67–9
(140–
(15)
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May 18, 2010:2201–9 N-Acetylcysteine in InfarctionIN. There were no significant differences in baseline renal
unction, the volume of contrast medium, and the number
f patients with high contrast volume of300 ml (Table 1).
he baseline creatinine concentration was elevated (105
mol/l) in 21 (17%) patients in the N-acetylcysteine and 16
13%) patients in the placebo group (p 0.53), whereas the
reatinine clearance was reduced (60 ml/min) in 24 (19%)
ersus 23 (19%; p  0.98).
Overall, CIN occurred in 18 (14%) patients in the
-acetylcysteine and 25 (20%) patients in the placebo group
p 0.28) with no significant differences in patients with or
ithout impaired creatinine clearance at baseline (Fig. 2).
he change in serum creatinine concentration and creati-
ine clearance for both treatment groups is shown in Figure
. Twenty-three percent of patients with high contrast doses
ad CIN (8 of 35 patients) versus 16% (35 of 213 patients;
 0.49), and there was no difference in N-acetylcysteine
ersus placebo in patients with high contrast volumes. In
otal, 5 patients needed dialysis (n  4 N-acetylcysteine vs.
 1 placebo; p  0.37).
In a multiple logistic regression model for development of
ephropathy, the strongest predictors of CIN were age,
emale sex, and creatinine clearance (p  0.05 for all).
-acetylcysteine use was not a predictor (p  0.53).
eperfusion injury. MRI. Results of MRI were available
or 111 (88%) patients in the N-acetylcysteine group and
or 109 (87%) patients in the placebo group (Fig. 1).
easons for not undergoing MRI are listed in Figure 1.
he median time between randomization and MRI was 3
ays (IQR 2 to 4) for both groups (p  0.38). There was
o difference in the primary end point MSI or in any
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Figure 2 Incidence of CIN
Overall incidence of contrast-induced nephropathy (CIN) in patients with creatininether parameter derived from MRI (Table 2). There was
lso no effect of N-acetylcysteine in different subgroups of
MI (anterior vs. nonanterior infarction, symptom du-
ation 6 h vs. 6 h, TIMI flow grade 3 vs. 3). In a
ultivariable linear regression model, the strongest pre-
ictors of MSI were post-PCI TIMI flow, symptom
uration, and anterior infarct location (p  0.01 for all).
-acetylcysteine use had no effect on MSI (p  0.21).
NZYMATIC INFARCT SIZE. The enzymatic infarct size as-
essed by the area under the curve of creatine kinase-MB
elease was similar between the N-acetylcysteine and pla-
ebo groups with 338 mol/l/h (IQR 290 to 383 mol/l/h)
ersus 313 mol/l/h (IQR 260 to 356 mol/l/h; p  0.13).
T-SEGMENT RESOLUTION. In 2 placebo patients, the ST-
egment resolution was not interpretable because the pa-
ients died during angioplasty. ST-segment resolution was
ot different between the groups (66.7%; IQR 45.6% to
00.0% vs. 68.1%; IQR 33.3% to 100.0%; p  0.57).
xidative stress. The baseline oxidative stress was similar
n both treatment groups (AOPP, 40.4 mol/l; IQR 27.5 to
4.3 mol/l vs. 40.9 mol/l; IQR 29.9 to 58.9 mol/l; p 
.30; oxidized low-density lipoprotein, 32.3 ng/ml; IQR
2.7 to 141.8 ng/ml vs. 34.8 ng/ml; IQR 16.4 to 95.1
g/ml; p  0.94). However, in the N-acetylcysteine group,
here was a reduction in AOPP for measurements at days 1
nd 2 and oxidized low-density lipoprotein at days 1, 2, and
in contrast to the placebo group (Fig. 4).
linical outcome. At 6-month follow-up, there were 12
9.6%) deaths in each group. Nonfatal reinfarctions oc-
urred in 3 (2.4%) after N-acetylcysteine and in 4 (3.2%)
0 ml/min >60 ml/min
N-acetylcysteine
Placebo
Creatinine clearance
4       23 102     100 
=0.46 P=0.08
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N-Acetylcysteine in Infarction May 18, 2010:2201–9fter placebo administration. New congestive heart failure
ccurred in 11 (8.7%) and 7 (5.6%), respectively. Thus, the
omposite major adverse cardiac event rate at 6-month
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Figure 3 Change in Serum Creatinine
Concentration and Creatinine Clearance
Median and interquartile range of serum creatinine concentration (A) and cre-
atinine clearance (B) before primary angioplasty (baseline), at days 1, 2, and
3. There was no significant difference for any of the values between the treat-
ment groups.
Magnetic Resonance ResultsTable 2 Magnetic Resonance Results
Variable
N-Acety
(n 
Area at risk, %LV 34.4 (28
Infarct size, %LV 17.4 (9.1
Myocardial salvage, %LV 13.2 (8.1
Myocardial salvage index 43.5 (25
Early microvascular obstruction, %LV 2.1 (0.8
Late microvascular obstruction, %LV 0.7 (0.2
LV ejection fraction, % 52.1 (43
LV end-diastolic volume, ml 145.0 (11
LV end-systolic volume, ml 68.4 (50Data are presented as median (interquartile range).
LV  left ventricular.ollow-up was 20.6% after N-acetylcysteine and 18.4% after
lacebo administration (p  0.77).
iscussion
n this prospective, randomized, single-blind trial,
-acetylcysteine significantly reduced oxidative stress.
owever, it was ineffective in preventing CIN and did not
ead to a measurable benefit in reperfusion injury in patients
ndergoing primary PCI for AMI. This lack of efficacy of
-acetylcysteine was independent of typical risk factors for
he development of CIN and also for confounders in
nfarction and MSI.
Because of its ability to scavenge oxygen free radicals
nd to counteract dye-induced renal vasoconstriction,
-acetylcysteine has been used in several previous trials
or CIN attenuation. Since the first positive results after
dministration of 600 mg N-acetylcysteine before and
fter elective contrast medium exposure plus hydration
18), there has been no conclusive evidence of the effec-
iveness (19 –21). Recently published trials in elective
ontrast administration in patients with chronic renal
nsufficiency suggested a dose-dependent effect (22,23).
his was confirmed in a nonblinded trial in patients with
MI in whom high-dose N-acetylcysteine (cumulative
ose 6,000 mg vs. 3,000 mg vs. placebo) was more
ffective in CIN prevention (8). Moreover, the dose-
ependent effect was accompanied by improved in-
ospital outcome. In the current single-blind trial, the
ame high-dose was administered; however, overall, there
as no benefit. This might be explained in part by the
ifferent dose of contrast medium (170 ml vs. 250 to 270
l). However, in the current trial, there was no preven-
ive effect in high contrast doses of 300 ml. Another
otential explanation might be the slightly better renal
unction at baseline (mean 81 and 85 ml/min vs. 75 to 79
l/min) (8). Overall, this difference was small, making it
nlikely that these differences had influenced the results.
t might be argued that N-acetylcysteine is only preven-
ive in patients with severely impaired renal function,
hich, due to the disease’s nature, cannot be assessed
ine Placebo
(n  109) p Value
8) 34.5 (28.6–41.7) 0.78
) 14.3 (8.0–26.2) 0.47
) 15.9 (9.6–24.5) 0.41
9) 51.5 (29.5–75.3) 0.36
1.9 (0.4–3.9) 0.38
0.6 (0.0–1.2) 0.25
2) 50.6 (41.6–58.6) 0.23
7.8) 136.0 (119.0–159.3) 0.19
6) 70.9 (49.3–89.1) 0.99lcyste
111)
.0–44.
–25.9
–26.5
.4–71.
–4.8)
–1.5)
.5–59.
8.8–16
.7–89.
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May 18, 2010:2201–9 N-Acetylcysteine in Infarctionefore primary PCI because of time constraints. In this
revious trial, under the specific circumstances of AMI
ith impaired systemic perfusion, high contrast volume, and
ithout optimal preventive measures, N-acetylcysteine pre-
ented CIN in patients irrespective of baseline creatinine
learance (8). In the current trial, there was no effect for
atients with and without impaired creatinine clearance,
nderscoring the lack of effect. Overall, the differences
etween the 2 trials can hardly explain the observed differ-
nces in CIN prevention and reflects the overall heteroge-
eity across N-acetylcysteine studies (21).
Negative study results raise a question of power.
espite performing an a priori sample power calculation
ased on previous results, which was adapted due to the
ower contrast volume, the estimate was still inaccurate
8). Based on the current results with 20% versus 14%
IN occurrence in the placebo and N-acetylcysteine
roups, respectively, a study would need 647 patients in
ach group to detect a difference with 80% power. As
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Figure 4 Oxidative Stress
Mean  SEM of the percentage of change in oxidative stress (advanced oxida-
tion protein products [A]; oxidized low-density lipoprotein [B]) from baseline
(pre-angioplasty) to post-angioplasty and days 1, 2, and 3. *p  0.05 for the
change in oxidative stress from baseline and in comparison to placebo. PCI 
percutaneous coronary intervention.here were virtually no changes in creatinine and creati- tine clearance and also on the clinical requirement for
enal replacement therapy, any clinical benefit is highly
uestionable. Given the current evidence of elective
ontrast administration with potential sample sizes of
2,200 patients to prevent CIN by N-acetylcysteine, it
ill be even more difficult to show any clinical benefit in
MI (20).
Another limitation of previous randomized trials of CIN
n elective and urgent cardiac catheterization is the limited
ollow-up beyond the first days after contrast exposure and,
espite beneficial effects in CIN prevention in some trials,
vidence of any improvement in outcome at long-term
ollow-up is still lacking (8,21,24,25). In the current study,
linical adverse events up to 6 months are reported among
ll randomized patients. However, there were no statistically
ignificant differences in the combined composite end point
etween treatment groups.
Reperfusion injury caused by the restoration of coronary
lood flow after an ischemic episode has been addressed
y numerous trials, and oxidative stress is one of the
otential targets (4). In previous trials, N-acetylcysteine
educed animal infarct sizes and led to preservation of left
entricular function in a small human trial (6,7,26).
owever, it also led to a more heterogeneous appearance
f the infarcts with increased ventricular arrhythmias
26). In addition, there are several positive effects on
latelet and vascular function (27,28). Similar to several
revious trials of reperfusion injury reduction, translation
f these beneficial effects into the clinical setting has been
isappointing (4). In comparison with nuclear tech-
iques, a very sensitive imaging method has been used
29). Therefore, it is unlikely that any difference in MSI
r infarct size has been missed. As there was virtually no
ffect on MSI, it is extremely unlikely that the trial was
nderpowered to detect differences in MSI. Furthermore,
n contrast to previous trials assessing MSI, a
-dimensional dataset of the area at risk and the infarct
ize was acquired, leading to a complete coverage of the
eft ventricle with further accuracy of the imaging method
14). In addition, the observed infarct size and MSI were
n the range of those of previously reported trials in
rimary PCI, reflecting the appropriateness of the imag-
ng method (11,16,30).
Experimental and clinical studies have shown that
eperfusion of ischemic myocardium induces oxidative
tress, which reduces the bioavailability of nitric oxide,
hereby leading to neutrophil accumulation, activation of
uperoxide radicals, and impairment of coronary blood
ow (4,5). N-acetylcysteine can reduce oxidative stress in
onjunction with fibrinolysis as early as 4 h after reper-
usion (31). In general, oxidative stress agents are highly
ctive, short-lived, and almost immediately react with
urrounding molecules at the site of formation. However,
hese species leave a detectable trace of modified oxida-
ive products. Therefore, the measured markers in the
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xidative stress. However, similar to previous trials, the
hange in oxidative stress did not result in a measurable
linical benefit (4).
tudy limitations. The primary study end point of CIN and
SI could not be determined in 0.7% and 12.4%, respectively.
ecause the number of patients in both groups was identical
nd the baseline characteristics of patients undergoing and
hose not undergoing end point assessment were similar, this
inimizes a potential selection bias. The exclusion of patients
rom MRI is inherent to this imaging method (11). Moreover,
hese patients were included in the analysis of clinical adverse
vents. Although the interventionalists coronary care unit
hysicians were blinded to all laboratory, electrocardiographic,
nd MRI measurements, they were aware of the group
ssignment. However, the single-blind design rules out a
otential patient bias. Finally, despite performing a multivari-
te analysis, it cannot entirely be ruled out that slight imbal-
nces in baseline clinical and procedural risk factors may have
ed to the diminished effect of N-acetylcysteine.
onclusions
igh-dose intravenous N-acetylcysteine reduces oxidative
tress after reperfusion for AMI. However, it does not provide
n additional clinical benefit to placebo with respect to ne-
hropathy and myocardial reperfusion injury in a nonselected
atient group undergoing primary PCI with moderate doses of
ontrast medium and optimal hydration given the powered
ffect size. Any true difference of intravenous N-acetylcysteine
dministration in addition to hydration is likely to be small and
resumably not clinically relevant.
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